TARS — Tarsus Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$76.36
+$2.31 (+3.11%)
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ. It is led by Bobak R. Azamian M.D., based in 17700 Laguna Canyon Road, Irvine, CA, United States, 92618, with about 370 employees. Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Latest reported TARS revenue for 2025-09-30 was $118.7M. Net income was -$12.6M. Revenue was up 15.6% from 2025-06-30 to 2025-09-30. TARS currently screens at market cap $2.66B.
Use this TARS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TARS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TARS SEC filings page. Lician reads the product cache first so this HTML stays unique to Tarsus Pharmaceuticals Inc even when a live quote feed is slow.
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Key Statistics
Market Cap
$2.66B
Volume
465,310
Previous Close
$71.45
Day Range
$69.77 – $71.15
P/B Ratio
7.71
EPS
-$3.07
Revenue
$182.95M
Net Income
-$115.55M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+948.6%
Profit Margin
-63.2%
Employees
370
TARS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $182.95M | $17.45M | $25.82M | $57.03M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$115.55M | -$135.89M | -$62.09M | -$13.83M |
| EPS (Diluted) | -$3.07 | -$4.62 | -$2.52 | -$0.67 |
Total Assets
$376.99M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$94.82M
Operating Cash Flow
-$83.03M
Free Cash Flow
$0.00
Tarsus Pharmaceuticals Inc Company Information
- Co-Founder, President, CEO & Chairman
- Bobak R. Azamian M.D.
- Headquarters
- 17700 Laguna Canyon Road, Irvine, CA, United States, 92618
- Website
- tarsusrx.com
- Phone
- 949 418 1801
- IPO / Founded
- 2020-10-16
- Sector
- Healthcare
- Industry
- Biotechnology